Skip to main content

and
  1. Article

    Open Access

    Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities

    The redirection of T cells has emerged as an attractive therapeutic principle in B cell non-Hodgkin lymphoma (B-NHL). However, a detailed characterization of lymphoma-infiltrating T cells across B-NHL entities...

    Tobias Roider, Marc A. Baertsch, Donnacha Fitzgerald in Nature Cell Biology (2024)

  2. Article

    Open Access

    Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

    Ex vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interve...

    Nora Liebers, Peter-Martin Bruch, Tobias Terzer in Nature Cancer (2023)

  3. Article

    Open Access

    Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

    Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics f...

    Sophie A. Herbst, Mattias Vesterlund, Alexander J. Helmboldt in Nature Communications (2022)

  4. No Access

    Article

    The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

    Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-tran...

    Lorenz Selberg, Peter Stadtherr, Sascha Dietrich in Bone Marrow Transplantation (2021)

  5. No Access

    Article

    BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

    Nora Liebers, Tobias Roider, Jan-Paul Bohn, Isabella Haberbosch in Leukemia (2020)